Subcutaneous daratumumab non-inferior to IV formulation in Phase III

Genmab A/S (CSE:GEN; Pink:GMXAY) said subcutaneous daratumumab met the co-primary endpoints of non-inferiority to IV daratumumab in the Phase III COLUMBA (MMY3012) trial to

Read the full 249 word article

User Sign In